Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

169 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing a new generation of vaccines and immunotherapeutic drugs Virometix is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases

150 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Off-the-shelf precision vaccines to prevent deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

PulseSight is an ophthalmology drug development company developing disruptive non-viral gene therapies with minimally-invasive delivery technology to treat major eye diseases. Our mission is to develop life-changing solutions for patients with diseases leading to sight loss.

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

125 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Platelet Secretome : a New Therapeutic Strategy Against Neurodegeneration InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

158 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Aiming at perfect skin regeneration MORE than 100 million patients develop scars from elective surgeries each year in developed countries alone.Sunogel is primarily directed toward the development of novel and regenerative therapeutics. At Sunogel, we investigate, incorporate and innovate functional three-dimensional scaffolds that can unlock the power of regeneration for damaged tissues, especially skin regeneration.

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Seed Therapeutics is pioneering the science of improving human health by creating “molecular glues”: novel therapeutics that degrade disease-causing proteins that have heretofore remained “undruggable.” Through ongoing collaborations with world-leading academic experts in the field, and in partnership with seasoned drug development and commercialization experts, Seed Therapeutics is establishing a growing pipeline of exciting drug candidates on a path to clinical and commercial success. Our mission is to positively impact human health by creating novel protein degradation therapeutics for the treatment of severe diseases for which health care professionals currently have limited options to offer to patients. Biotechnology, Biotherapeutics, Cell …

201 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We create ophthalmic therapeutic bio factories to sustainably treat major eye diseases. Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. EyeCET stands for the eye ciliary muscle electro-transfection technology, which uses electroporation to deliver plasmids coding for therapeutic proteins in the eye. EyeCET is safe and non-viral, and it enables the ciliary muscle cells to sustainably produce therapeutic proteins locally. Eyevensys believes its EyeCET technology can improve short and long-term therapeutic outcomes, greatly enhancing patient compliance and significantly …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Newcells ophthalmology business was acquired by Axol Bioscience Axol Bioscience Ltd. acquires ophthalmology business from Newcells Biotech Newcells Biotech is pleased to announce the acquisition of our ophthalmology business by Axol Bioscience Ltd., a leading drug discovery partner specialising in the development of in vitro models and specialist services. Learn more: https://axolbio.com/retinal-organoid-ophthalmology/ Induced pluripotent stem cells (iPSCs), Cellular reprogramming and differentiation, Supply of iPSC derived cells for drug development, Sourcing samples for human disease cell lines, Drug Transport Studies, RPE, Retinal Epithelia, Stem Cell Models, Disease Modelling, Retinal Epithelial Model, Toxicity, and Retina

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Laigo's SureTAC platform enables rapid therapy development for removal of disease-driving membrane proteins #laigobio Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs

146 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss. Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its …

75 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Innovation for your health and well-being. Pharmaceutical company, R&D oriented dedicated to the development and marketing of senolytic compounds, food supplements and drugs against aging, age-related degenerative diseases and cancer.

81 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Coave therapeutics Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success …

97 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

We're on a mission to cure blindness with our transformational platform of advanced therapies. Aurion Biotech, Inc. (Aurion Biotech) is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care. CAUTION: New Drug—Limited by Federal (or United States) law to investigational use.

73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases (IRDs). With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients. Gene Therapy, Ophthalmology, and Rare diseases

89 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Precision treatment of immune disorders Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-CatchTM technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients.

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AveXis is now Novartis Gene Therapies Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). Follow us on LinkedIn: https://www.linkedin.com/company/novartis-gene-therapies/ How to reach us: Novartis Gene Therapies 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: gtx.communications@novartis.com Office Phone: 847.572.8280 Toll-free Phone: 844.428.3947 Gene Therapy, Synthetic Biology, and Spinal Muscular Atrophy

221 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering therapies for oncogene-driven cancers Haptena is a biotech company founded in 2025 by Professors Chiara Ambrogio and Roberto Chiarle, with the goal of advancing next-generation immunotherapies for genetically defined cancers. Our mission is to bridge the precision of targeted therapies and the transformative potential of immune-based treatments to deliver more durable options for patients with some of the most challenging tumors.

241 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Evolution. Adaptation. Future. Phage-based solutions to combat bacteria. - Prevention - Diagnosis - Treatment "One Health" personalized treatments. biotecnología, microbiología, investigación, biomedicina, bacteria, phage, and phage therapy

185 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

RhyGaze is pioneering a transformative approach with cone optogenetics, which has the potential to revolutionize vision restoration for patients suffering from blindness. pharmaceutical development, optogenetics, gene therapy, ophthalmology, and pharmaceutical research

117 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Applying pathbreaking science to transform the lives of patients with severe retinal neurodegenerative diseases GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP

209 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovation. Applied. Founded in 2021, POLYGON Therapeutics is a Paris-based biotechnology company developing precision cardio-immunology therapies targeting inflammatory drivers of cardiovascular disease. The company combines translational human biology, biomarker-driven development and immunology expertise to develop novel therapeutic approaches in cardiovascular disease.

228 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

264 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Curing blindness with regenerative cell therapies. StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials - for FASTER tissue regeneration, SAFER cell therapies and EASIER cell delivery.

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

565 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to discovering and advancing novel therapeutics that halt or slow the ageing process for healthier lives Genflow Biosciences plc (LON: GENF) (OTCQB: GENFF) is an emerging leader in the field of longevity research with R&D facilities in Belgium and a U.S. office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the aging process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results. Managed by an experienced team with decades of experience in the pharmaceutical and …

106 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Overcoming Challenges, Innovating Hope An innovative molecule to reshape the future of the brain Glyx Therapeutics is dedicated to transforming the lives of patients by pioneering innovative treatments for neurodegenerative disorders with urgent, unmet medical needs. Our work focuses on tackling orphan tauopathies and Alzheimer’s disease, bringing hope and solutions to those facing these challenging conditions.

174 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

120 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Smart active ingredients, safer sun exposure Catalonia Exponential Leader 2023 Roka Furadada’s mission is to reduce the incidence of skin cancer through research, development and production of active ingredients and medical devices, with high efficiency and low toxicologic and environmental impact OUR PURPOSE Roka Furadada wants to help to prevent and reduce the incidence of skin cancer. HOW ARE WE GOING TO DO IT? Developing the first intelligent ultra violet radiation filter: SMART UV, with new molecules that entail therapeutic activity to prevent and treat diseases associated with sun exposure. Cosmetics, Raw Materials , Ingredients, Cosmetic Ingredients, Sunscreen, Sun protection …

132 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes. AXPAXLITM (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is Ocular’s leading investigational candidate for retinal disease, based on its proprietary ELUTYXTM technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME). Retina, Retinal Disease, Wet AMD, NPDR, DME, Anti-VEGF, Tyrosine Kinase Inhibitors, Ocular Drug Delivery, Sustained Delivery, Ophthalmic Therapies, and Ophthalmology

69 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

140 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Delivery of vision care EyeD Pharma is a clinical stage pharmaceutical company dedicated to improving the life of patients suffering from ophthalmic diseases with unmet medical needs such as glaucoma or dry eye. We develop innovative therapeutic solutions based on sustained release polymeric micro-implants and inserts.

127 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Reversing Neurodegeneration - Restoring Life GeneCode is developing small-molecule drugs that bind and activate GDNF (Glial cell line-Derived Neurotrophic Factor) receptors for the treatment of Parkinson’s disease (PD) and other neurodegenerative conditions.

119 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Bringing precision to the power of biologics with pioneering use of synthetic nanoclays for regenerative medicine. Renovos Biologics Ltd. (Renovos) is a biotech/medtech company focussed on the development of its patented synthetic nanoclay, RENOVITE®, as a drug delivery platform for regenerative medicine and beyond. Regenerative Medicine, Biomaterials, Drug Delivery, Medical Devices, Pharmaceuticals, Stem Cells, Orthopaedics, and Biotechnology

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Regain control with personalized muscle regeneration MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

514 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Making Regenerative Medicine Accessible Roumai Medical is developing next-generation biotechnologies in regenerative medicine and human-machine interface to meet the unmet clinical needs of millions of patients worldwide.

207 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

296 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We are developing the future of drug discovery with a platform to discover, develop, and deliver drug candidates for challenging targets. Sign up for our quarterly newsletter to keep up with our progress: https://lnkd.in/eCH3d6ay

153 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease

257 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Une entreprise spécialisée dans le développement de thérapies transformatrices ayant un impact sur la longévité. Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, …

263 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

428 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Applying world-leading molecular genetics to tackle age-related diseases and increase human healthspan. SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells. At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We’re using ground-breaking cell technologies to revolutionise global food production - starting with pork Uncommon Bio began with cell-based meat and pioneered RNA delivery innovations, which evolved into their most recent spin out which is focusing on changing medicine through multi-targeting. Their polysaccharide-based delivery platform enables multi-pathway cell programming, offering a safe, efficient and scalable alternative to multi-target therapies. The company is initially targeting severe lung diseases like idiopathic pulmonary fibrosis and is backed by industry leaders from BioNTech and top investors, including Sam Altman, Balderton, Lowercarbon, and Redalpine. science+art, biotech, mRNA, IPF, Pulmonary fibrosis, and delivery

561 similar entities Type: Startup Activities: biotech deeptech foodtech Technologies: Synthetic Biology

A biotech startup redefining our most basic understanding of the ageing process Based at the Babraham Research Campus in Cambridge, LinkGevity is a pioneering drug discovery company founded on ground-breaking research in longevity science. Our goal is to change the paradigm of ageing, paving the way for people to live healthier lives for longer. Contact us on info@linkgevity.com

129 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Outsmarting complex diseases with more intelligent medicines Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell …

90 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class therapeutics for autoimmune disorders We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases

117 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are driving research finding treatments and cures for blinding retinal diseases. The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, Usher syndrome, Stargardt disease, Leber congenital amaurosis, age-related macular degeneration, and the spectrum of retinal degenerative diseases.

50 similar entities Type: SMB Activities: deeptech

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

582 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Uniqueness of Individualized Neoantigen Cancer Vaccine to Reshape the Future of Early-Stage Cancer Treatment Cancer immunotherapy Transgene (Euronext: TNG) is a clinical-stage biotechnology company focused on individualized therapeutic vaccines

166 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering cellular rejuvenation using epigenetic restoration to reverse diseases of aging At Life Biosciences, we are on a mission to reverse age-related diseases. Our platform, termed epigenetic restoration, has been shown to rejuvenate cells in preclinical models with profound therapeutic effect. It has the potential to rejuvenate cells and restore function in many age-related diseases. We are the sole company with intellectual property covering the therapeutic use of our epigenetic restoration technology. We are also the only company to have received FDA approval to advance this technology into human clinical studies. While our initial clinical trial is for optic neuropathies, …

93 similar entities Type: Startup Activities: biotech deeptech silvertech Technologies: Synthetic Biology

AgeX Therapeutics is focused on the development and commercialization of novel therapeutics targeting human aging. AgeX Therapeutics, Inc. (“AgeX”) is a biotechnology company focused on the emerging field of interventional gerontology. Its technology platform is built upon a modern understanding of the molecular basis of cellular immortality and regenerative biology. Leveraging technology licensed from parent company BioTime, Inc. as well as Geron Corporation, AgeX is leading the development of novel therapeutics targeting some of the largest market opportunities associated with an aging population.

62 similar entities Type: Startup Activities: deeptech biotech silvertech Technologies: Synthetic Biology

Combating disease and aging by reversing age-related cellular changes through epigenetic reprogramming. 199 Biotechnologies is an early-stage company developing first-in-class therapies that target the fundamental mechanisms of aging, with the goal of transforming the landscape of age-related disease treatment and prevention.

61 similar entities Type: Startup Activities: biotech deeptech

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

172 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vision-restoring engineered cell-based therapeutics & in vivo reprogramming. Tenpoint Therapeutics is a vision-restoring engineered cell-based therapeutics company. We are embracing a new opportunity to fundamentally reshape the future for people with ocular diseases. We have an ambitious goal with global impact.

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Helping people live longer, healthier lives. Centenara Labs is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its experienced drug discovery and development team applies a deep understanding of the biology of aging, alongside technological advances in biopharmaceutical R&D, to progress a new generation of medicines that will help people to age better and live longer.

66 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology